Enterprise Europe Network

Digital therapy planning for predictive cancer treatment

Country of origin:
Country: 
HUNGARY
Opportunity:
External Id: 
TOHU20210630001
Published
30/06/2021
Last update
08/07/2021
Expiration date
09/07/2022

Keywords

Partner keyword: 
Applications for Health
Cytology, Cancerology, Oncology
Cellular and Molecular Biology
Medical/health software
Artificial intelligence related software
Molecular diagnosis
Diagnostic equipment
EXPRESS YOUR INTEREST

Summary

Summary: 
A Hungarian SME have been developing a medical software system designed to help selecting the most suitable targeted therapies based on molecular genetic alterations in cancer. The tool facilitates physicians’ work to select personalized and effective therapies for cancer patients. The company is looking for private hospitals, health centres with precision oncology wards, precision oncology related molecular diagnostic labs for commercial agreement with technical assistance or license agreement.

Description

Description: 

The oncology software developed by the Hungarian start-up company provides artificial intelligence (AI) based digital therapy planning. It facilitates the selection of the most suitable and efficient targeted treatment by organizing and weighting scientific evidence in a predictive way.

With the help of molecular diagnostics, the company establishes a detailed molecular profile (comprehensive diagnostic panels) and determines the molecular point of attack for targeted therapies. Then recommends the comprehensive molecular profile tests to oncologists.

During therapy planning supported by digital devices, the medical team reviews and captures the patient’s medical history and enters the results of the molecular diagnostic tests of the patient’s tumor into this online decision support system. If these tests are not available or are proven to be insufficient, the necessary molecular diagnostic tests will be performed. The results are analyzed by the molecular biologists or info-bionic experts using the oncology software. The results of the analysis will be discussed at an online video conference by a special board of experts, called the virtual molecular tumor board (VMTB) – consisting of oncologists, molecular biologists and geneticists. In accordance with the recommendation of the experts or upon the request of the treating physician, the treating physician may also participate in the expert meeting. Based on the VMTB’s recommendation, a patient-specific digital therapy plan is created, which is used by the treating physician for the therapeutic decision.

It has been developed for oncologists, publicly and privately funded oncology institutions and insurance companies.

The company is looking for partners under commercial agreement with technical assistance to support the transfer of the technology with the provision of additional support services. It is also open to have a licence agreement with licensee partners.

Advantages & innovations

Cooperation plus value: 
The oncology software uses the results of molecular diagnostics and bioinformatics to rank supporting evidence in real time during digital therapy planning, by using its proprietary AEL (aggregated evidence level) algorithm, thus supporting the oncologist's decision. The software not only collects evidence based on the patient’s molecular profile, but also ranks them based on the AEL algorithm, providing exceptional and unique assistance in digital therapy planning. The software - if molecular information allows - analyses the entire molecular profile, and not merely individual molecular targets. The company conducts detailed (comprehensive) molecular profile-based therapy planning. This medical software system helps selecting the most suitable targeted therapies based on molecular genetic alterations in cancer. The tool facilitates physicians’ work to select personalized and effective therapies for cancer patients. This special medical oncology software is a type of artificial intelligence that based on more than 20 thousand scientific evidence, taking into account more than 26 thousand precision oncology rules and using a unique mathematical algorithm, ranks genetic alterations in the patient’s tumour as well as the related therapeutic options in a transparent, objective and reproducible way.

Stage of development

Cooperation stage dev stage: 
Already on the market

Partner sought

Cooperation area: 
- Type of partner sought: (Precision) oncologists with private practice, private institutes, private hospitals, and health centres with oncology wards, (precision) oncology related molecular diagnostic labs and centres that apply NGS [new generation sequencing] solutions, national/private health insurance companies, ministries of health. - Specific area of activity of the partner: (precision) oncology - Task to be performed: Oncologist: mutual referral of patients, hospitals, health centres: integrating company’s system into their process of treating oncology patients under licence agreement or commercial agreement with technical assistance. Health insurance companies, ministries of health: let the company introduce itself and justify the financial benefit behind the company’s solution. Type of agreement: Commercial agreement with technical assistance or licence agreement.